Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology)

N/A

Report date: 2025/04/22 14:43:21

Base Information

Drug NameAnti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology)
Drug Alias NameAutologous anti-BCMA/GPRC5D CAR-T cell therapy自体抗BCMA/GPRC5D CAR-T细胞疗法Anti-BCMA/GPRC5D Bispecific CAR T-Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMAAnti-GPRC5D
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXuzhou Medical University (Xzmu)
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A